Coagulo Medical Technologies, Inc.
Coagulo Medical Technologies is transforming medicine with the first portable and connected precision-medicine platform for smarter management of coagulation, enabling better healthcare outcomes for everyone. The company combines patent-pending coagulation assays, cutting-edge microfluidic technology, and proprietary data analytics to deliver accessible and personalized diagnosis and management of coagulation-related diseases.
Coagulo Medical Technologies, Inc.
2000 Commonwealth Ave, Suite 200, Auburndale, MA, 02466, United States
What We Do
Coagulo has developed the world’s first testing system that can detect, identify and quantify the effect of all currently-prescribed anticoagulants, providing actionable results to healthcare providers in under 10 minutes.
Coagulo’s testing platform is transforming diagnosis and treatment for pediatric patients, allowing for less invasive and more rapid diagnostic tools that do not result in additional harm to vulnerable patients.
Coagulo’s approach to personalized coagulation phenotyping is propelling research and discovery to unlock the next generation of clinical treatments for patients requiring coagulation management.
The world’s first precision-medicine platform capable of pinpointing abnormalities across the entire clotting cascade and delivering clinically-valuable information.
Application Area
Key People
President and Chief Science Officer
Chairman and Chief Executive Officer
Chief Medical Officer
Chief Technology Officer
Head of Regulatory Affairs
News & Updates
Coagulo to present data on the use of the POC Testing System for the detection of apixaban in patients with intracranial hemorrhage
Coagulo will present data at ISTH 2023.
Case report published with Mass General Brigham
The case report discusses the use of Coagulo’s POC testing to monitor argotraban treatment in a patient with antiphospholipid syndrome, HIT, and COVID-19 pneumonia.
Publication on Coagulo’s technology to detect anticoagulation resistance
The publication discusses prediction of thrombotic events in pediatric patients requiring ECMO treatment with Texas Children’s Hospital.
Coagulo awarded a multi-million dollar contract with the Department of Defense
The contract is for the development of a ruggedized coagulation testing system to be used in austere conditions.
Massachusetts General Hospital presents clinical data on Coagulo’s technology
The data presentation is for complex anticoagulant management at the 2022 Society of Critical Care Medicine Congress.
Finalist in the American College of Emergency Physicians Medical Device competition
Coagulo was recognized as a finalist in this prestigious competition.